Helix BioPharma Corp.

Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development

2026-06-30 17:15:00

Vancouver, British Columbia – TheNewswire - June 30 , 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today announced the appointments of Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations . The appointments further strengthen Helix's executive leadership team as the Company prepares for its planned U.S. securities exchange listing, advances the next stage of development for L-DOS47 through LDOS007, the Company's planned Phase IB/Randomized Phase II study in first-line non-small cell lung cancer (NSCLC), and continues building the legal, governance and operational infrastructure required to support its next phase of growth.   “The next stage of Helix's evolution demands a different kind of company than the one we were building two years ago,” said Thomas Mehrling, MD, PhD, Chief Executive Officer of the Company. “As we prepare for our planned U.S. securities exchange listing and advance L-DOS47 into its next stage of clinical development, we are deliberately strengthening every part of the organization. From our legal and governance framework to our clinical execution capabilities, we are building the leadership team required to support the next phase of Helix's growth.”

Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026

2026-06-12 18:15:00

Vancouver, British Columbia – TheNewswire - June 12, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today reported financial results and the filing of the Company's unaudited interim financial statements as of and for the three- and nine-month periods ended April 30, 2026 (the “Financial Statements” ), the management's discussion and analysis ( “MD&A” ), and the certifications of the Chief Executive Officer and Chief Financial Officer (respectively, “CEO” and “CFO” ) relating to the Financial Statements (collectively, the “Interim Filings” ). All values are in Canadian dollars unless stated otherwise.   “Since the beginning of the year, our focus has been on securing the capital necessary to support Helix's near-term operating and development objectives,” said Thomas Mehrling, MD, PhD, Chief Executive Officer of the Company. “With the successful completion of our recent private placement, we have made substantial progress toward our objective of establishing approximately twelve months of operating runway. This financing strengthens our ability to execute against our strategic priorities, including ongoing preparations for a U.S. exchange listing as we work to expand access to capital, advance L-DOS47 toward the clinic, and create long-term shareholder value.”

Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures

2026-06-03 17:15:00

Vancouver, British Columbia – TheNewswire - 3 June, 2026 – Helix BioPharma Corp. (TSX: “ HBP ”, OTC PINK: “ HBPCF ”, FRANKFURT: “ HBP0 ”) (“ Helix ” or the “ Company ”), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, announces that it has closed a non-brokered private placement (the “ Offering ”) of unsecured convertible debentures of the Company (each, a “ Convertible Debenture ”). The Company issued 3,673 Convertible Debentures for aggregate gross proceeds of C$3,673,000 pursuant to the Offering. The principal amount and any unpaid accrued interest of the Convertible Debentures will be due and payable 14 months from the closing date of the private placement (the “ Maturity Date ”). Each Convertible Debenture will bear interest at 25.00% per annum, calculated on a simple interest basis. If the Convertible Debentures are not repaid on or prior to the Maturity Date, the outstanding principal amount of the Convertible Debentures may be convertible by the holder on the Maturity Date into common shares in the capital of the Company (each, a “ Share ”) at a price of C$1.42 per Share, being the market price of the Shares as of the price reservation date, less the permitted 20% discount in accordance with TSX policies (the “ Conversion Price ”). If the Convertible Debentures are not repaid on or prior to the Maturity Date, any accrued but unpaid interest of the Convertible Debentures may be convertible by the holder on the Maturity Date into Shares at a conversion price of the greater of: (i) the Conversion Price; and (ii) the volume weighted average trading price of the Shares listed on TSX during the five (5) trading days immediately preceding the relevant date, less the TSX permitted discount (the “ Interest Conversion Price ”).

Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options

2026-05-22 16:15:00

Toronto, Ontario – TheNewswire - May 22, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today announced that the board of directors has granted 1,297,000 incentive stock options to directors, officers, employees and consultants of the Company pursuant to its equity compensation plan. Each stock option is exercisable to acquire one common share of the Company at an exercise price of $1.63 per share for a period of five years from the date of grant. The options are subject to various vesting provisions in accordance with the terms of the Company's equity compensation plan and the applicable option agreements.

Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy

2026-05-13 16:15:00

Toronto, Ontario – TheNewswire - 13 May, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, is pleased to announce the following appointments, effective immediately: Zachary T. Stadnyk, former TSX Life Sciences Lead and a biotech capital markets executive, has been appointed to the Company's Board of Directors (the “Board” ), and Natalia L. Butterworth, Director, Corporate Secretarial and Governance at ARO Consulting Inc., has been appointed Corporate Secretary of the Company.   Mr. Stadnyk brings more than 15 years of experience across biotechnology, capital markets, and public company leadership, including serving as Head of Life Sciences at the TSX and TSXV, where he advised biotech issuers, boards and institutional investors on public listings, capital formation and strategic positioning, with deep experience in public market execution. Over the course of his career, he has led and supported over $100 million in institutional financings, contributed to strategic transactions including the $435 million acquisition of The Supreme Cannabis Company by Canopy Growth, and advised public companies across the biotech, healthcare and AI sectors.